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Clinical signs and symptoms included fever (100% of cases),
polyarthralgia (90%), followed by headache (80%), anemia
(70%), and rash. A mild-to-moderate myelosuppression of
all hematological lines characterized 8 cases of 11 (72.7%),
while increased serum transaminases were associated in
63.6% of patients. Three patients of ours deserved hospi-
talization (mean 10.8 days of admission), and ﬁve more
cases were followed on Day-Hospital basis (for a median
75-day period); in four patients a treatment with i.v. high-
dosage human immunoglobulins was performed. Elevated
levels of speciﬁc serum anti-Parvovirus B19 IgM antibod-
ies were detected in all cases. In a 33-year-old female a
severe anemia and a persisting headache, vomiting, and
neck stiffness, led to RBC transfusion and a diagnosis of
meningoencephalitis, with positive search of IgM antibodies
and Parvovirus B19 viremia (detected by RT-PCR) in the cere-
brospional ﬂuid which lasted up to three months, despite
treatment with i.v. serum immunoglobulins.
Conclusion: Parvovirus B19 infection may play a signif-
icant role also in adult, immunocompetent subjects, and
the disease sometimes is not mild and self-limiting, requir-
ing admission and/or frequent outpatient interventions in a
signiﬁcant number of cases. The causes supporting a per-
sistant infection in immunocompetent subjects have not
been investigated to date, as well as the pathogenesis of
myelosuppression and severe polyartrhalgia. Symptomatic
Parvovirus B19 infection is still an underestimated clinical
condition, and therapeutic perspectives are extremely lim-
ited until now.
doi:10.1016/j.ijid.2010.02.641
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Background: Epidemics and pandemics have had a great
mpact on the course of human history. As such emergence
nd re-emergence of diseases of high risk to the individ-
al, and/or the community, are of speciﬁc interest and
oncern to public health systems, whether they be in devel-
ped or developing countries. Ebola viruses represent prime
xamples of such emerging pathogens. Ebola outbreaks are
npredictable, with high severity and fatality rates. This
igh case fatality rate of Ebola virus infection and the lack
f approved vaccines and therapeutics resulted in classiﬁ-
ation of Ebola viruses as biosafety level 4 pathogens and
otential bioweapons by the WHO and the CDC. The main
oal of this work is to identify epitopes within the viral pro-
eins of Sudan ebolavirus (strain Gulu) that are targets of the
umoral immune response in survivors. Epitope speciﬁc anti-
odies are important indicators of survival from this deadly
isease and can serve as templates for the development of
ynthetic or vectored vaccines
Methods: Using standard cloning techniques the Sudan
bolavirus (strain Gulu) genes for all seven structural pro-
eins were cloned and sequenced. For viral protein 24
VP24), 30 (VP30), 40 (VP40) and NP further expression con-
tructs were generated containing a Flag tag epitope for
etection. These proteins were expressed in 293T cell using
tandard techniques and transfection efﬁciency was con-
rolled by using a VP40-GFP fusion protein construct.
Following expression, viral proteins were isolated and
ested by western blot analysis.he expression of the recombinant viral protein of
bolavirus (strain Gulu) by western blot (WB) analysis
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decision-making as regards treatment with Acyclovir. We
recommend a multicenter epidemiological study to conﬁrm
the efﬁcacy of these criteria.
doi:10.1016/j.ijid.2010.02.644462 14
Results: Initial results comparing immmunoreactivity
etween survivor and non survivor serum samples have
evealed different recognition patterns to the individual
iral proteins; VP24, VP40 and NP.
Conclusion: Identiﬁcation of speciﬁc targets of the
uccessful adaptive immune response during Ebolavirus
nfection will hopefully be useful for development of next
eneration diagnostics and development of synthetic or vec-
ored vaccines.
oi:10.1016/j.ijid.2010.02.642
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Background: Rotavirus is a major causative pathogen of
evere diarrhea in humans and animals. On the basis of VP6
ntigen, Rotaviruses are classiﬁed into seven groups (A-G),
mong which only groups A-C rotaviruses cause infection in
umans. Group B rotavirus (GBR) was ﬁrst detected in China
n 1982 as a cause of adult diarrheal outbreaks. Although
he detection of GBR had been limited in China, GBR has
een found in India since 1998, in Bangladesh since 2000,
nd in Myanmar in 2007. Because of limited data, genetic
haracteristics of GBR have not been well known so far.
Methods: GBRs detected recently in India (IDH-084 in
007, IC-008 in 2008), Bangladesh (Bang117 in 2003), and
yanmar (MMR-B1 in 2007) were analyzed genetically. Full
enome sequences of these strains were determined by RT-
CR and direct sequencing methods. Sequence data was
nalyzed phylogenetically by MEGA4 program with those of
BRs reported previously.
Results: Sequences of all genes of GBRs, including those
f animals, were classiﬁed into three clusters, i.e., Chinese
ineage, India-Bangladeshi-Myanmar lineage, and animal
bovine and murine) lineages. Each strain showed high
equence identity among the same lineage (e.g.,95.6-100%
mong India-Bangladeshi-Myanmar lineage). The evolution-
ry rate of all segment genes of GBRs was estimated to be
.89-2.05310-3 nucleotide substitutions per site per year,
sing the synonymous substitutions between CAL-1(1998 in
ndia) and IDH-084, CAL-1 and IC-008, and Bang373(2000 in
angladesh) and Bang117.
Conclusion: Full genome sequences of recent group B
uman rotaviruses were determined and revealed the pres-
nce of two major lineages in human GBRs by phylogenetic
nalysis. Compared to the strains detected in different
ears, the substitution rate was estimated for the ﬁrst time
or all the gene segments. It was similar to those from par-
ial sequence data reported previously and was comparable
o the rate of other rapidly evolving RNA viruses. Furtherternational Congress on Infectious Diseases (ICID) Abstracts
ccumulation of genetic data is needed for resolution of
cological features of group B rotaviruses.
oi:10.1016/j.ijid.2010.02.643
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Background: To deﬁne the criteria for diagnosis of Herpes
implex Encephalitis, (HSE), in children.
Methods: Charts of all patients, admitted to Moﬁd
hildren’s Hospital in Tehran, Iran, from 1999 to 2005,
ith clinically suspected Herpes Simplex Encephalitis or
eningo-encephalitis were reviewed. We documented rel-
vant variables, including demographic data, signs and
ymptoms at presentation, and laboratory investigations
uch as CSF analysis, PCR and the results of neuro-imaging.
atients were categorized into three groups according to
he diagnosis of HSE being deﬁnite, probable or possible.
iagnosis was deﬁned as ‘deﬁnite’ in the presence of clin-
cal symptoms compatible with HSE and detection of the
athogen, or antigen-detection from the cerebrospinal ﬂuid
y PCR. Diagnosis was designated as ‘probable’ in the pres-
nce of clinical symptoms of HSE and abnormal analysis of
SF, or abnormalities in neuro-imaging compatible with HSV
nfection.
Clinical symptoms compatible with HSE with normal CSF,
r clinical manifestations not characteristic of HSV infec-
ion but with abnormal analysis of CSF, were placed in the
ategory of ‘possible’ HSE.
Results: According to above criteria, deﬁnite HSE was
iagnosed in seven; probable HSE in nine, and possible HSE
n two patients.
Conclusion: We think every patient who has encephali-
is with symptoms suggestive of HSE, should be graded
nto one of the following diagnostic categories: deﬁnite,
robable, or possible HSE; otherwise the diagnosis should
e rejected. This classiﬁcation would help the clinician in
